» Articles » PMID: 36128637

Thymus and Activation-regulated Chemokine (TARC) As Treatment Response Marker for Paediatric Hodgkin Lymphoma: A Pilot Study

Overview
Journal Br J Haematol
Specialty Hematology
Date 2022 Sep 21
PMID 36128637
Authors
Affiliations
Soon will be listed here.
Abstract

Classical Hodgkin lymphoma (cHL) is characterised by malignant Hodgkin Reed-Sternberg cells located in an inflammatory microenvironment. Blood biomarkers result from active cross-talk between malignant and non-malignant cells. One promising biomarker in adult patients with cHL is thymus and activation-regulated chemokine (TARC). We investigated TARC as marker for interim and end-of-treatment response in paediatric cHL. In this multicentre prospective study, TARC levels were measured among 99 paediatric patients with cHL before each cycle of chemotherapy and were linked with interim and end-of-treatment remission status. TARC levels were measured by enzyme-linked immunosorbent assay. At diagnosis, TARC levels were elevated in 96% of patients. Plasma TARC levels declined significantly after one cycle of chemotherapy (p < 0.01 vs. baseline) but did not differ at interim assessment by positron emission tomography (p = 0.31). In contrast, median plasma TARC at end of treatment was significantly higher in three patients with progressive disease compared to those in complete remission (1.226 vs. 90 pg/ml; p < 0.001). We demonstrate that, in paediatric patients, plasma TARC is a valuable response marker at end-of-treatment, but not at interim analysis after the first two chemotherapy cycles. Further research is necessary to investigate TARC as marker for long-term progression free survival.

Citing Articles

CCL17, CCL22 and their receptor CCR4 in hematologic malignancies.

Zou S, Liu B, Feng Y Discov Oncol. 2024; 15(1):412.

PMID: 39240278 PMC: 11379839. DOI: 10.1007/s12672-024-01210-x.


[Expression and clinical significance of CCL17, CCL22, and CCR4 in newly diagnosed multiple myeloma].

Xiao Z, Zou S, Yi C, Zhao Y, Wu L, Feng Y Zhonghua Xue Ye Xue Za Zhi. 2024; 45(7):672-677.

PMID: 39231772 PMC: 11388129. DOI: 10.3760/cma.j.cn121090-20231230-00349.


NOTCH1 fusions in pediatric T-cell lymphoblastic lymphoma: A high-risk subgroup with CCL17 (TARC) levels as diagnostic biomarker.

Kroeze E, Kleisman M, Kester L, Scheijde-Vermeulen M, Sonneveld E, Buijs-Gladdines J Hemasphere. 2024; 8(7):e117.

PMID: 38948925 PMC: 11208779. DOI: 10.1002/hem3.117.


Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma.

Gonzalez-Kozlova E, Huang H, Jagede O, Tuballes K, Del Valle D, Kelly G Cancer Res Commun. 2024; 4(7):1726-1737.

PMID: 38934093 PMC: 11247952. DOI: 10.1158/2767-9764.CRC-24-0252.


Nivolumab plus Brentuximab vedotin +/- bendamustine combination therapy: a safe and effective treatment in pediatric recurrent and refractory classical Hodgkin lymphoma.

Greve P, Beishuizen A, Hagleitner M, Loeffen J, Veening M, Boes M Front Immunol. 2023; 14:1229558.

PMID: 37583696 PMC: 10423930. DOI: 10.3389/fimmu.2023.1229558.


References
1.
Castellino S, Geiger A, Mertens A, Leisenring W, Tooze J, Goodman P . Morbidity and mortality in long-term survivors of Hodgkin lymphoma: a report from the Childhood Cancer Survivor Study. Blood. 2010; 117(6):1806-16. PMC: 3056636. DOI: 10.1182/blood-2010-04-278796. View

2.
Andre M, Girinsky T, Federico M, Reman O, Fortpied C, Gotti M . Early Positron Emission Tomography Response-Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial. J Clin Oncol. 2017; 35(16):1786-1794. DOI: 10.1200/JCO.2016.68.6394. View

3.
Meignan M, Gallamini A, Haioun C . Report on the First International Workshop on Interim-PET-Scan in Lymphoma. Leuk Lymphoma. 2009; 50(8):1257-60. DOI: 10.1080/10428190903040048. View

4.
Barnes J, Lacasce A, Zukotynski K, Israel D, Feng Y, Neuberg D . End-of-treatment but not interim PET scan predicts outcome in nonbulky limited-stage Hodgkin's lymphoma. Ann Oncol. 2010; 22(4):910-915. DOI: 10.1093/annonc/mdq549. View

5.
Jones K, Vari F, Keane C, Crooks P, Nourse J, Seymour L . Serum CD163 and TARC as disease response biomarkers in classical Hodgkin lymphoma. Clin Cancer Res. 2012; 19(3):731-42. DOI: 10.1158/1078-0432.CCR-12-2693. View